Literature DB >> 3018080

Tumor-specific idiotype vaccines. I. Generation and characterization of internal image tumor antigen.

S Raychaudhuri, Y Saeki, H Fuji, H Kohler.   

Abstract

The concept of idiotype vaccines against tumor-associated antigens (TAA) was tested in the DBA/2 L1210 lymphoma subline, L1210/GZL. Monoclonal antibodies against a TAA that cross-reacts with the envelope glycoprotein gp52 of the mammary tumor virus were used to make hybridoma anti-idiotype antibodies (Ab2). In this report we describe the characterization of monoclonal anti-idiotypic antibodies against the combining site of 11C1 (Ab1), which recognizes a shared determinant of gp52 of mouse mammary tumor virus (MMTV) and the TAA of L1210/GZL. Hybridomas expressing the internal image of gp52 were screened by an idiotype inhibition assay. Mice sensitized with radiated L1210/GZL cells produced specific delayed type hypersensitivity (DTH) against the Ab2 hybridoma. Five Ab2 hybridomas were selected and were used to immunize DBA/2 mice. Such immunized animals showed specific DTH reaction against a challenge with the L1210/GZL tumor cells. Similar results were obtained in mice immunized with purified Ab2. Fluorescence-activated cell sorter analysis demonstrated that fluorescence staining of L1210/GZL cells by 11C1 can be completely inhibited with preabsorption on Ab2 hybridoma cells. Mice immunized with 2F10 and 3A4 coupled to keyhole limpet hemocyanin (KLH) contained antibodies binding to MMTV. But only in mice immunized with 2F10-KLH was significant inhibition of L1210/GZL tumor growth observed. Collectively, these results indicate that certain anti-idiotypic antibodies can mimic the MMTV gp52 antigen, as well as the gp52-like epitope expressed on the L1210/GZL tumor cells. These properties of anti-idiotypic antibodies mimicking TAA could be exploited for making idiotype vaccines against tumors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3018080

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Possible role of anti-idiotypic antibodies in the induction of tumor immunity.

Authors:  R C Kennedy; E M Zhou; R E Lanford; T C Chanh; C A Bona
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

2.  Idiotype vaccine for tumor by anti-idiotypic antibody prepared against anti-(bacillus Calmette Guèrin)BCG monoclonal antibody.

Authors:  J Sasaki; T Tamagake; S Narita; C R Ahsan
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 3.  Idiotypic vaccines and infectious diseases.

Authors:  J R Hiernaux
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

4.  Murine monoclonal anti-idiotope antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys.

Authors:  P Chattopadhyay; J Starkey; W J Morrow; S Raychaudhuri
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

5.  The role of humoral and cellular immunity in patients developing human anti-murine immunoglobulin antibody responses after radioimmunotherapy.

Authors:  C Kosmas; S Man; A A Epenetos; N S Courtenay-Luck
Journal:  Br J Cancer Suppl       Date:  1990-07

6.  Regulation of serum antibodies induced in syngeneic rats after administration of monoclonal antibody MT10:21.

Authors:  S M North; J L Gurin
Journal:  Immunology       Date:  1989-01       Impact factor: 7.397

7.  Induction of delayed-type hypersensitivity responses by monoclonal anti-idiotypic antibodies to tumor cells expressing carcinoembryonic antigen and tumor-associated glycoprotein-72.

Authors:  K Irvine; J Schlom
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

8.  Tumor idiotype vaccines. VIII. Analysis of protective idiotype in sera and hybridomas derived from tumor-bearing mice with long-term survival.

Authors:  J J Chen; H Kohler
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

9.  Molecular mimics of the tumour antigen MUC1.

Authors:  Tharappel C James; Ursula Bond
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

10.  Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry.

Authors:  Ana M H Vázquez; Nely Rodrèguez-Zhurbenko; Ana M V López
Journal:  Front Oncol       Date:  2012-11-20       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.